These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4277 related articles for article (PubMed ID: 28650338)

  • 1. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
    Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
    J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
    Peters S; Kerr KM; Stahel R
    Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for the treatment of non-small cell lung cancer.
    Muller M; Schouten RD; De Gooijer CJ; Baas P
    Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
    Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
    Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
    BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 214.